Intellia Therapeutics (NTLA) led the rally for CRISPR stocks on Monday, promising ahead of a gene-editing approach in inherited liver conditions. The news sent NTLA shares to a record high.
Researchers tested a single dose of Intellia’s gene-editing therapy in patients with abnormalities caused by abnormal protein accumulation. After 28 days, three patients receiving the higher dose found Protein was reduced by an average of 87%.
There are also no side effects. This is important because Intellia was the first to test cell editing within the body. Other approaches include removing sick cells, modifying cells, and reinserting patients’ cells. Intellia’s approach may be more diverse.
“This is the first clinical data to suggest that we can precisely edit targeted cells within the body to treat genetic diseases within a single intravenous injection of CRISPR,” said chief executive John Leonard. Intellia said in a written statement.
In today’s stock market, NTLA shares jumped 50.2 percent to 133.43 partner shares. Regeneron Pharmaceuticals (REGN) fell 1.4% to 542.70 after increasing in previous operations. At the same time, the shares of Crispr Therapeutics (CRSP) increased 6.4% to 151.63. leave medicine (Edit) Popped 5% to 43.99 and beam therapy (BEAM) closed at 108.85, up 16%.
NTLA Stock Rockets by Futures
Intellia studies gene-editing drug in patients with transthyretin amyloidosis and polyneuropathy. In this disease, an abnormal protein called Transthyretin, or TTR, accumulates on nerves and causes systemic problems.
Researchers test two doses of gene-editing drug At the lower dose, patients experienced an average 52% decrease in TTR. The higher dose group had an average 87% reduction. One of those patients showed a 96% decrease in TTR over the course of 28. days, which helps increase NTLA stock.
on the contrary Standards of care typically reduce that protein by 80 percent, Intellia said in a press release. Alnylam pills (ALNY) Keeps chronic treatment for the same condition, shares fell 5.2 percent to 166.20 on Monday.
George Yancopoulos, CEO of Regeneron, said: “This is an exciting introduction for people living with this deadly disease and for the entire scientific community working to increase the potential of genetic medicine through cutting-edge research and technology,” said George Yancopoulos, CEO of Regeneron. Regeneron CEO Yancopoulos said in a written statement.
CRISPR stocks also jumped.
The news is bullish for NTLA stocks and the universe of CRISPR stocks.
Other gene-editing methods have been tested ex vivo, including treating Crispr and blood diseases. Vertex Pharmaceuticals (VRTX). In the ex vivo approach, researchers were able to validate the cell transformation prior to refilling.
Intra-body correction is not possible. which involves replacing cells at their sites in the body But the in vivo gene-editing process is expected to be less time-consuming and less expensive. Intellia’s test is the first to prove that in vivo methods can work in humans.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
You may like:
Put Fido first: Millennials, Gen Z are pushing animal health stocks to new heights.
Why Crispr’s Gene-Editing Jump Wasn’t Enough to Save Vertex Stock
Watch the IBD Investment Strategy Show for actionable market insights.
Want to earn quick profits and avoid big losses? Try SwingTrader
Looking for the next big stock market winner? Start with these 3 steps.